MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2025 International Congress

    A case of Parkinson’s Disease whose Daily Levodopa/Carbidopa Intestinal Gel dose has been determined by her spouse and prevented Long-term Fluctuations

    Y. Okuma (Izunokuni, Japan)

    Objective: To present a case of Parkinson’s disease (PD) whose daily levodopa/carbidopa intestinal gel (LCIG) dose has been determined by her spouse and prevented long-term…
  • 2025 International Congress

    Investigation of the mode of action of a new device for the application of therapeutic vibro-tactile stimulation to the fingertips on brain activity

    K. Frey, J. Hügel, L. Lowinski, G. Rennert, C. Castañeda González, I. Klingmann, C. Böhler, C. Hauptmann (Plankstadt, Germany)

    Objective: The development of a new therapeutic glove for the vibro-tactile stimulation of the fingertips was accompanied by investigations on its mode of action on…
  • 2025 International Congress

    Comparative Safety of Different Routes of Apomorphine Administration in Parkinson’s Disease: A Systematic Review and Meta-Analysis

    A. Al Midani, A. Ahmad, O. Razouk, L. Mohamedali, M. Al Khalidi, B. Al Karam, A. Khater (Sharjah, United Arab Emirates)

    Objective: To assess the safety profiles of inhaled, sublingual, and subcutaneous apomorphine in patients with Parkinson’s disease (PD). Background: Apomorphine is a direct-acting D1/D2 agonist…
  • 2025 International Congress

    Design of ORCHESTRA Study: Practical Experiences With Foslevodopa/Foscarbidopa Treatment in Advanced Parkinson’s Disease

    A. Johansson, E. Pekkonen, L. Dorresteijn, P. Schwingenschuh, J. Szász, L. Bergmann, M. O'Meara, J. Parra, M. Südmeyer (Helsinki, Finland)

    Objective: To describe the practical management of foslevodopa/foscarbidopa (LDp/CDp) for treating advanced Parkinson’s disease (aPD) in routine clinical practice using data collected through a patient…
  • 2025 International Congress

    Timing And Type Of Adverse Events Following Long-Term Treatment With Levodopa–Entacapone–Carbidopa Intestinal Gel (LECIG) Infusion – Data From The ELEGANCE Interim Analysis

    N. Smith, B. Amlani (Reading, United Kingdom)

    Objective: To evaluate the type and timing of occurrence of treatment-emergent adverse events (AEs) in people with advanced Parkinson’s disease (PD) following up to one…
  • 2025 International Congress

    Combining Machine Learning and Linear Mixed Models to Estimate Medication Effect in People with Parkinson’s Disease

    A. Castro Mejia, S. Sapienza, L. Pavelka, R. Kruger, J. Klucken (Belvaux, Luxembourg)

    Objective: To estimate medication effect, as the score difference between MDS-UPDRS III in OFF and ON-state, using a minimal set of clinical features. Background: The…
  • 2025 International Congress

    Repetitive Transcranial Magnetic Stimulation For Freezing Of Gait And Motor Function In Parkinson’s Disease: A Systematic Review And Meta-Analysis Of Randomized Controlled Trials

    J. Pitton Rissardo, A. Fornari Caprara (Camden, USA)

    Objective: To evaluate the effects of repetitive transcranial magnetic stimulation (rTMS) on motor function, freezing of gait (FOG), and mobility in patients with Parkinson’s disease…
  • 2025 International Congress

    Apomorphine Sublingual Film’s Efficacy in Elderly Patients with Parkinson’s Disease: Post-hoc Analysis of Study CTH-301

    F. Moreira, L. Wojtecki, W. Jost, D. Santos Garcia, J. Kassubek, M. Fonseca, H. Brigas, G. Harrison-Jones, I. Pijuan (Duesseldorf, Germany)

    Objective: This study evaluated the efficacy of apomorphine sublingual film (SL-APO) in elderly (≥70 years) and younger (<70 years) patients over the long term. Background:…
  • 2025 International Congress

    Association Between Heterozygous Loss-of-Function Variants in the MCOLN1 Gene and α-Synucleinopathies

    CX. Ying, XH. Chen, ZD. Cen, W. Luo (Hangzhou, China)

    Objective: To evaluate the association between heterozygous loss-of-function variants in the MCOLN1 gene and α-synucleinopathies. Background: Lysosomes play a crucial role in cellular waste disposal,…
  • 2025 International Congress

    The neuroprotective effects of Echinacoside on α-synuclein fibril-induced Parkinson’s disease mice model

    Q. Zhao, S. Bu, Z. Wang, L. Jin (Shanghai, China)

    Objective: This study further investigates the ameliorative effects of ECH on neurobehavioral abnormalities and nigrostriatal dopaminergic system impairment in α-synuclein preformed fibrils (α-Syn PFFs)-induced PD…
  • « Previous Page
  • 1
  • …
  • 307
  • 308
  • 309
  • 310
  • 311
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley